Open AccessC-Fos Digital Expression Analysis in Human PapillomavirusRelated Oral Squamous Cell Carcinoma
Author(s) -
Aristeidis Chrysovergis,
Vasileios Papanikolaou,
Nicholas Mastronikolis,
Despοina Spyropoulou,
Μαρία Αδαμοπούλου,
Evangelos Tsiambas,
Vasileios Ragos,
Dimitrios Peschos,
Dimitrios Roukas,
Chara Stavraka,
Athanasios Niotis,
Efthymios Kyrodimos
Publication year - 2021
Publication title -
asian pacific journal of cancer biology
Language(s) - English
Resource type - Journals
ISSN - 2538-4635
DOI - 10.31557/apjcb.2021.6.2.117-121
Subject(s) - immunohistochemistry , cancer research , oncogene , c fos , signal transduction , cell , transcription factor , biology , gene expression , gene , cell cycle , pathology , medicine , microbiology and biotechnology , genetics
Background: Fos Proto-Oncogene (c-Fos) represents a well analyzed gene involved in solid malignancies’ development and progression. The corresponding protein forms heterodimer with c-jun, a strong transcription factor. C-Fos/c-Jun complex influences critically the intracellular signal transduction to the nucleus. Our aim was to detect and evaluate c-Fos protein expression patterns in oral squamous cell carcinomas (OSCC) tissues. Materials and Methods: Fifty (n=50) formalin-fixed, paraffin-embedded primary OSCCs tissue sections were used. Immunohistochemistry and digital image analysis were implemented for identifying and evaluating c-Fos protein expression levels, respectively. Results: C-Fos protein over expression (moderate to high imunostaining intensity values) was observed in 28/50 (56%) tissue cores, whereas low expression rates were detected in the rest of the examined cases (22/50- 44%). C-Fos overall expression was strongly associated with the stage and grade of the examined tumors (p=0.014, p=0.003, respectively) and also with Human papillomavirus (HPV) persistent infection (p=0.004). c-Fos up regulation is frequently observed in OSCCs. Conclusion: C-Fos high expression levels are correlated with an aggressive phenotype (advanced stage/lymph node metastasis) in patients with OSCC, especially in HPV positive cases, especially High Risk subtypes. Due to its elevated oncogenic activity, c-Fos should be a target for novel therapeutic strategies in OSCC combined or not with other oncogenes involving in signaling transduction pathways.